New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
05:29 EDTPLXProtalix announces first patient treated in Phase I/II study of Fabry patients
Protalix BioTherapeutics announced that the first patient has been treated in the company's phase I/II clinical trial of Fabry patients with PRX-102. PRX-102 is the company's proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme in development as a long-term enzyme replacement therapy for the treatment of Fabry disease.
News For PLX From The Last 14 Days
Check below for free stories on PLX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2014
13:48 EDTPLXProtalix to host conference call
Subscribe for More Information
August 28, 2014
13:17 EDTPLXPfizer, Protalix announce FDA approves ELELYSO pediatric indication
Subscribe for More Information
10:40 EDTPLXProtalix holder Bio-Cell in agreement to seek purchasers for 4.4M shares
Bio-Cell, a 10.7% stake holder in Protalix, announced that on August 13, Bio-Cell entered into an agreement with Barak Capital pursuant to which Barak will seek potential purchasers for 4,400,000 shares of Protalix Common Stock, following which Bio-Cell entered into agreements with a number of Israeli purchasers for the sale and purchase of said shares for a consideration of approximately $2.47 per share .Bio-Cell intends to use the consideration received by it pursuant the Transaction, to pay its expected tax liability to the Israeli Tax Authority in connection with Bio-Cellís proposed distribution of shares of Issuer's Common Stock, as a dividend to its shareholders on a pro rata basis.. Such expected tax liability was set forth in a pre-ruling delivered to Bio-Cell by the ITA. Bio-Cell expects that following the Dividend payment, it will no longer own any shares of Issuer's Common Stock. However, as of the date hereof, there is no certainty that the Dividend will be paid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use